ARCA biopharma to receive US patent for methods of heart failing treatment with genetic tests based bucindolol ARCA biopharma, Inc. , a biopharmaceutical firm developing genetically targeted therapies for heart failing and other cardiovascular diseases, announced that it has received a Notice today of Allowance from the U.S. Patent and Trademark Office for its U.S. Once issued, the patent provides coverage for ways of treating heart failing patients with bucindolol based on genetic testing. Bristow, President and Chief Executive Officer of ARCA. .This article is definitely republished with kind authorization from our friends at The Kaiser Family members Foundation. You can view the entire Kaiser Daily Health Plan Report, search the archives, or join email delivery of in-depth coverage of health policy developments, debates and discussions. The Daily Health Plan Report is released for Kaisernetwork.org, a free program of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Kaiser and Company Family members Foundation. All rights reserved.. Very Young Babies Feeling Touch Differently: – MONDAY, Oct. 19, 2015 – – When you touch a newborn’s hands or foot, the infant doesn’t identify that sensation the same manner older babies, children and adults do, a fresh study suggests.